HCXT-2001 + emvistegrast

HCXT-2001 + emvistegrast is a proposed all-oral combination regimen under investigation for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The combination pairs HCXT-2001, an oral macrocyclic peptide inhibitor of the interleukin-23 receptor (IL-23R) originally developed by PepStar Therapeutics, with emvistegrast (GS-1427), Gilead Sciences' internally developed oral small-molecule inhibitor of the α4β7 integrin. By combining an IL-23R blocker with an integrin inhibitor, the regimen aims to target two distinct, clinically validated pathways in IBD to achieve synergistic therapeutic efficacy. Gilead acquired the oral IL-23R program from PepStar in October 2026 and has proposed the combination as a potential once-daily oral regimen, though clinical testing of the combination has not yet commenced.

Other names

GS-1427 + HCXT-2001GS-1427 and HCXT-2001GS1427 and HCXT-2001GS 1427 and HCXT-2001HCXT-2001 + GS-1427HCXT-2001 and emvistegrastHCXT2001 and emvistegrastHCXT 2001 and emvistegrastemvistegrast + HCXT-2001emvistegrast and HCXT-2001